The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

4 Jan 2024 17:30

Arix Bioscience PLC (ARIX) Holding(s) in Company 04-Jan-2024 / 17:30 GMT/BST


TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

ARIX Bioscience PLC

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an “X”)

An acquisition or disposal of voting rights

 

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

 

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Weiss Asset Management LP

City and country of registered office (if applicable)

Wilmington, Delaware, USA

4. Full name of shareholder(s) (if different from 3.)v

Name

Brookdale International Partners, L.P., Brookdale Global Opportunity Fund

City and country of registered office (if applicable)

Brookdale International Partners, L.P.: Albany, NY, USA

Brookdale Global Opportunity Fund: Grand Cayman, Cayman Islands

5. Date on which the threshold was crossed or reachedvi:

January-2-2024

6. Date on which issuer notified (DD/MM/YYYY):

January-4-2024

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

0.00

5.19

5.19

129,389,508

Position of previous notification (if

applicable)

 

N/A

 

N/A

 

N/A

 

             

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. A

 

 

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/ Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

CFD

N/A

N/A

Cash Settlement

6,725,000

5.19

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

6,725,000

5.19

 

                   

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an “X”)

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Weiss Asset Management LP

 

 

 

Brookdale International Partners, L.P.

0.00

2.90

2.90

 

 

 

 

Weiss Asset Management LP

 

 

 

Brookdale Global Opportunity Fund

0.00

2.29

2.29

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

Weiss Asset Management LP is the Investment Manager to Brookdale Global Opportunity Fund and Brookdale International Partners, L.P.

         

 

Place of completion

Boston, USA

Date of completion

January-4-2024

 


Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:HOL
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 2.3. Major shareholding notifications
Sequence No.:295596
EQS News ID:1808641
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
16th Mar 20237:01 amEQSUnaudited NAV for February 2023
14th Feb 20236:19 pmEQSPortfolio company Disc Medicine announces $62.5 million financing
6th Feb 20236:00 pmEQSDirector/PDMR Shareholding
6th Feb 20235:00 pmEQSDirector/PDMR Shareholding
6th Feb 20238:00 amEQSUnaudited NAV for January 2023
6th Feb 20237:00 amEQSUnaudited NAV for January 2023
30th Jan 20238:00 amEQSUnaudited NAV for December 2022
30th Jan 20237:00 amEQSUnaudited NAV for December 2022
26th Jan 20238:00 amEQSBoard Change
26th Jan 20237:00 amEQSBoard Change
5th Jan 20235:20 pmEQSPortfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
5th Jan 20234:21 pmEQSPortfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
30th Dec 20228:01 amEQSPortfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
30th Dec 20227:01 amEQSPortfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
12th Dec 20228:00 amEQSUnaudited NAV for November 2022
12th Dec 20227:01 amEQSUnaudited NAV for November 2022
6th Dec 20228:00 amEQSArix to Present at Mello Investment Trusts & Funds
6th Dec 20227:00 amEQSArix to Present at Mello Investment Trusts & Funds
1st Dec 20227:45 amRNSDirector/PDMR Shareholding
9th Nov 20228:00 amEQSUnaudited NAV for October 2022
9th Nov 20227:00 amEQSUnaudited NAV for October 2022
28th Oct 20227:00 amEQSDirector/PDMR Shareholding
28th Oct 20227:00 amEQSDirector/PDMR Shareholding
20th Oct 20224:30 pmEQSHolding(s) in Company
20th Oct 20224:30 pmEQSHolding(s) in Company
14th Oct 20227:00 amEQSPortfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
14th Oct 20227:00 amEQSPortfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
11th Oct 20227:00 amEQSUnaudited NAV for September 2022
11th Oct 20227:00 amEQSUnaudited NAV for September 2022
5th Oct 20227:00 amEQSDirector/PDMR Shareholding
5th Oct 20227:00 amEQSDirector/PDMR Shareholding
3rd Oct 20224:32 pmEQSArix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
3rd Oct 20224:31 pmEQSArix Portfolio Company Aura Biosciences Presents Interim Phase 2 Data Highlighting Belzupacap Sarotalocan (AU-011) Suprachoroidal Efficacy and Safety at AAO 2022
15th Sep 20227:01 amEQSUnaudited NAV for August 2022
15th Sep 20227:00 amEQSUnaudited NAV for August 2022
12th Aug 20227:00 amEQSUnaudited NAV for July 2022
12th Aug 20227:00 amEQSUnaudited NAV for July 2022
10th Aug 20226:05 pmEQSArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 20226:05 pmEQSArtios initiates Phase 2 study of Polθ Inhibitor ART4215 in Combination with PARP Inhibitor Talazoparib in BRCA Deficient Breast Cancer
10th Aug 20225:46 pmEQSPortfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 20225:46 pmEQSPortfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics
10th Aug 20227:01 amEQSInterim Results for the Six Months Ended 30 June 2022
10th Aug 20227:01 amEQSArix Bioscience plc Announces Changes to Board of Directors
10th Aug 20227:01 amEQSArix Bioscience plc Announces Changes to Board of Directors
10th Aug 20227:00 amEQSInterim Results for the Six Months Ended 30 June 2022
3rd Aug 20227:00 amEQSNotice of Results & Investor Presentation
3rd Aug 20227:00 amEQSNotice of Results & Investor Presentation
22nd Jul 20227:00 amEQSUnaudited NAV for June 2022
22nd Jul 20227:00 amEQSUnaudited NAV for June 2022
22nd Jun 20224:45 pmEQSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.